LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company ...
Model output · Signal date 2026-10-15
Lb Pharmaceuticals Inc (LBRX) Stock Forecast Oct. 15, 2026
Analysis updated on Oct. 15, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 5111 stocks scored
Rank correlation · 90D
20.0%
Spearman, 182 dates
Market Cap
$1.10B
small-cap · #60 of 60 peers
Summary
Lb Pharmaceuticals Inc (LBRX) stock forecast summary
Our AI ranks Lb Pharmaceuticals Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Lb Pharmaceuticals Inc is a small-cap company with a market capitalization of $1.10B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For LBRX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 20.0%, measured on 182 forecast dates between 2025-11-06 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -18.0%, measured on 224 forecast dates between 2025-11-06 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LBRX included.
Follow LBRX freePrice
LBRX price chart and AI forecast
Cross-section · 2026-10-15
How LBRX ranks among 5111 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Lb Pharmaceuticals Inc (LBRX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | LBRX | Rank |
|---|---|---|
| Market Cap | $1.10B | 60/60 |
| P/B Ratio | 3.30x | 36/41 |
| EPS | $-4.84 | – |
| Book Value/Share | $10.30 | – |
| FCF/Share | $-2.99 | – |
Profitability & Margins
| Metric | LBRX | Rank |
|---|---|---|
| ROE | -28.8% | 26/36 |
| ROA | -26.5% | 34/41 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | LBRX | Rank |
|---|---|---|
| Current Ratio | 15.08x | 10/56 |
| D/E Ratio | 0.09x | 38/46 |
| Financial Leverage | 1.09x | 39/46 |
| Working Capital | $332M | 44/56 |
Cash Flow
| Metric | LBRX | Rank |
|---|---|---|
| Operating Cash Flow | -$96M | 39/56 |
| Free Cash Flow | -$97M | 33/47 |
| Capital Spending | -$450K | 6/47 |
Income Statement
| Metric | LBRX | Rank |
|---|---|---|
| Net Income | -$96M | 25/43 |
| R&D Expense | $76M | 53/55 |
Dividend & Shareholder Information
| Metric | LBRX | Rank |
|---|---|---|
| Shares Outstanding | 32M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $355M | 98.2% of assets |
| Cash & Short-term Investments | $283M | 78.3% of assets |
| Total Liabilities | $29M | 8.1% of assets |
| Short-term Debt | $20M | 5.5% of assets |
Quarterly Financial Reports
LBRX quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Lb Pharmaceuticals Inc (LBRX) industry peers
Companies classified under the same SEC industry code as Lb Pharmaceuticals Inc (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| LBRX Lb Pharmaceuticals Inc | ▲ | $1.10B |
| LLY Eli Lilly & Co | ▶ | $1.14T |
| JNJ Johnson & Johnson | ▼ | $611.90B |
| ABBV Abbvie Inc. | ▶ | $500.75B |
| MRK Merck & Co., Inc. | ▶ | $363.59B |
| NVS Novartis Ag | ▼ | $280.27B |
| AZN Astrazeneca Plc | ▼ | $251.15B |
| ABT Abbott Laboratories | ▼ | $182.04B |
| NVO Novo Nordisk A S | ▼ | $169.41B |
| PFE Pfizer Inc | ▼ | $166.49B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $126.35B |
| BMY Bristol Myers Squibb Co | ▶ | $121.09B |
| SNY Sanofi | ▼ | $98.05B |
| GSK Gsk Plc | ▼ | $96.58B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $80.48B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.45B |
| ONC Beone Medicines Ltd. | ▲ | $39.96B |
| RPRX Royalty Pharma Plc | ▲ | $33.92B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.32B |
| ZTS Zoetis Inc. | ▼ | $31.11B |
| TAK Takeda Pharmaceutical Co Ltd | ▶ | $30.24B |
| ATHE Alterity Therapeutics Ltd | ▶ | $25.65B |
| ZLAB Zai Lab Ltd | ▶ | $25.26B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.28B |
| GMAB Genmab A/S | ▶ | $23.73B |
| UTHR United Therapeutics Corp | ▼ | $23.16B |
| INSM Insmed Inc | ▶ | $21.36B |
| VTRS Viatris Inc | ▶ | $20.03B |
| ASND Ascendis Pharma A/S | ▲ | $14.97B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.61B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.69B |
| CORT Corcept Therapeutics Inc | ▲ | $12.56B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.07B |
| ELAN Elanco Animal Health Inc | ▼ | $11.27B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.67B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.64B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.63B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.82B |
| CYTK Cytokinetics Inc | ▲ | $8.82B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.50B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.25B |
| ABVX Abivax S.A. | ▼ | $7.26B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.10B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $6.93B |
| ALKS Alkermes Plc. | ▲ | $6.73B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.67B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.16B |
| AMRX Amneal Pharmaceuticals, Inc. | ▲ | $6.04B |
| BLTE Belite Bio, Inc | ▲ | $6.01B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.97B |
| LGND Ligand Pharmaceuticals Inc | ▶ | $5.88B |
| BLRX Biolinerx Ltd. | ▶ | $5.43B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.19B |
| ERAS Erasca, Inc. | ▲ | $5.14B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $5.08B |
| TVTX Travere Therapeutics, Inc. | ▲ | $5.02B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $4.98B |
| COGT Cogent Biosciences, Inc. | ▶ | $4.88B |
| MANE Veradermics, Inc | ▲ | $4.74B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.18B |
Where LBRX sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Lb Pharmaceuticals Inc (LBRX) stock news
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ...
The poster describes the ongoing, pivotal Phase 3 trial (NOVA-2) and open label extension trial (NOVA-3) designed to evaluate the efficacy, safety and long-term effectiveness of LB-102 as a once-daily ...
FAQ
Lb Pharmaceuticals Inc (LBRX) stock forecast FAQ
What is the Lb Pharmaceuticals Inc (LBRX) stock forecast?
Our AI ranks Lb Pharmaceuticals Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Lb Pharmaceuticals Inc stock predictions?
For LBRX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 20.0%, measured on 182 forecast dates between 2025-11-06 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -18.0%, measured on 224 forecast dates between 2025-11-06 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Lb Pharmaceuticals Inc forecasts updated?
Lb Pharmaceuticals Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
Which companies are Lb Pharmaceuticals Inc's industry peers?
60 issuers in our coverage, LBRX included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.